{"transactions":[{"id":732428,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-18T21:58:14.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":17340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full upon the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17340,"derivative":{"exercise_price":36.73,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":17340},"source":{"system":"sec-edgar","filing":"0001644348-26-000007","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000164434826000007/edgardoc.xml","form_type":"4"}},{"id":747460,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:32:51.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":42000,"derivative":{"exercise_price":1.19,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001644348-26-000003","document":"form4-06052026_080643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000164434826000003/form4-06052026_080643.xml","form_type":"4"}},{"id":748090,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-05T11:58:21.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":12500,"derivative":{"exercise_price":30.91,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-258432","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526258432/ownership.xml","form_type":"4"}},{"id":758405,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:24.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000066","document":"wk-form4_1780091721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000066/wk-form4_1780091721.xml","form_type":"4"}},{"id":933436,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-01-22T13:08:56.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option will vest and become exercisable on January 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":43.14,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001193125-26-018702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526018702/ownership.xml","form_type":"4"}},{"id":1110094,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-16T21:08:06.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":19959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19959,"derivative":{"exercise_price":16.99,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":19959},"source":{"system":"sec-edgar","filing":"0002036042-25-000032","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000032/edgardoc.xml","form_type":"4"}},{"id":1117353,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:30:45.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":33500,"derivative":{"exercise_price":0.95,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001415889-25-016276","document":"form4-06092025_080633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000141588925016276/form4-06092025_080633.xml","form_type":"4"}},{"id":1127184,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:38:36.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":15.55,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001636282-25-000068","document":"wk-form4_1748896689.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000068/wk-form4_1748896689.xml","form_type":"4"}},{"id":1484433,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:44:40.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024."}],"balance_after":67500,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0001415889-24-016238","document":"form4-06102024_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000141588924016238/form4-06102024_080637.xml","form_type":"4"}},{"id":1513786,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-16T20:10:16.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":11323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":11323,"derivative":{"exercise_price":39.29,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":11323},"source":{"system":"sec-edgar","filing":"0000950170-24-061085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024061085/ownership.xml","form_type":"4"}},{"id":1729353,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-27T21:33:03.000Z","date":"2023-11-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 50,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":10.39,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-066143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023066143/ownership.xml","form_type":"4"}},{"id":1810617,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-10T16:26:35.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":22297,"price":37,"value":824989.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date."}],"balance_after":102312,"source":{"system":"sec-edgar","filing":"0001628280-23-028889","document":"wk-form4_1691699187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000162828023028889/wk-form4_1691699187.xml","form_type":"4"}},{"id":1858249,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T21:55:15.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":21500,"derivative":{"exercise_price":5.59,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-23-036456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000120919123036456/doc4.xml","form_type":"4"}},{"id":1869104,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T19:15:36.000Z","date":"2023-06-02","kind":"sale","planned":false,"acquired":false,"shares":4647,"price":37.06,"value":172217.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on June 01, 2022."}],"balance_after":80015,"source":{"system":"sec-edgar","filing":"0001628280-23-020720","document":"wk-form4_1685747726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000162828023020720/wk-form4_1685747726.xml","form_type":"4"}},{"id":2047257,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-01-24T16:00:35.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":45456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":45456,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":45456},"source":{"system":"sec-edgar","filing":"0001214659-23-001044","document":"marketforms-58268.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465923001044/marketforms-58268.xml","form_type":"4"}},{"id":2047256,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2023-01-24T16:00:35.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":26864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date."}],"balance_after":84662,"source":{"system":"sec-edgar","filing":"0001214659-23-001044","document":"marketforms-58268.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465923001044/marketforms-58268.xml","form_type":"4"}},{"id":2236076,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:00:37.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":24000,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-036148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919122036148/doc4.xml","form_type":"4"}},{"id":2241234,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-06T21:59:15.000Z","date":"2022-06-02","kind":"grant","acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 2, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":19500,"derivative":{"exercise_price":13.56,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001209191-22-034634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000120919122034634/doc4.xml","form_type":"4"}},{"id":2243820,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-06-03T17:56:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":91164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested."}],"balance_after":91164,"derivative":{"exercise_price":39.93,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":91164},"source":{"system":"sec-edgar","filing":"0001214659-22-007823","document":"marketforms-56337.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465922007823/marketforms-56337.xml","form_type":"4"}},{"id":2243819,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-06-03T17:56:46.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":57798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date."}],"balance_after":57798,"source":{"system":"sec-edgar","filing":"0001214659-22-007823","document":"marketforms-56337.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1576263/000121465922007823/marketforms-56337.xml","form_type":"4"}},{"id":2338151,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":15200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit granted by the Issuer under an Issuer Stock Plan that was subject to performance-based vesting conditions (each, an \"Issuer PRSU\") that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration (with all the performance-based vesting conditions associated with such Issuer PRSU being deemed achieved at the greater of actual completed performance at the Effective Time or at target for any Issuer PRSU), subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2338150,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":38850,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":80.08,"underlying":"Common Stock","underlying_shares":38850},"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2338149,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":132000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":36.33,"underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2338148,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":21462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, as of the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Company after December 12, 2021 under the Issuer's 2021 Long-Term Incentive Plan (each, a \"2022 Issuer RSU\") that was unvested and outstanding as of immediately prior to the Effective Time was substituted automatically with a Parent restricted stock unit with respect to that number of shares of Parent common stock that is equal to the product obtained by multiplying (1) the total number of Issuer Common Stock subject to the 2022 Issuer RSU immediately prior to the Effective Time by (2) the RSU Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2338147,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":6660,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":21462,"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2338146,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-11T16:12:08.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":9086,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 842 shares acquired on March 2, 2022, pursuant to Arena's 2019 Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":28122,"source":{"system":"sec-edgar","filing":"0001628280-22-005891","document":"wf-form4_164703310389595.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005891/wf-form4_164703310389595.xml","form_type":"4"}},{"id":2445258,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-05T17:00:49.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":21462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":36366,"source":{"system":"sec-edgar","filing":"0001628280-22-000340","document":"wf-form4_164142002647728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022000340/wf-form4_164142002647728.xml","form_type":"4"}},{"id":2674016,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T16:30:26.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":17700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting."}],"balance_after":17700,"derivative":{"exercise_price":7.69,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001209191-21-039462","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919121039462/doc4.xml","form_type":"4"}},{"id":2675006,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-06-09T21:39:02.000Z","date":"2021-06-02","kind":"grant","acquired":false,"shares":16333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders."}],"balance_after":16333,"derivative":{"exercise_price":32.29,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":16333},"source":{"system":"sec-edgar","filing":"0001209191-21-039241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1644348/000120919121039241/doc4.xml","form_type":"4"}},{"id":2762283,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2021-04-02T20:10:55.000Z","date":"2021-03-16","kind":"exercise","acquired":false,"shares":12600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units (\"2020 PRSUs\"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the performance period from the grant date through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein."},{"field":"shares","element":"transactionShares","label":"F1","text":"On March 16, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units (\"2020 PRSUs\"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the performance period from the grant date through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units (\"2020 PRSUs\"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the performance period from the grant date through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The amount reported in Column 7 of Table II represents the common shares that vested. The 2020 PRSUs have now fully vested and no common shares remain issuable thereunder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units (\"2020 PRSUs\"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the performance period from the grant date through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein."}],"balance_after":0,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":12600},"source":{"system":"sec-edgar","filing":"0001209191-21-024879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121024879/doc4.xml","form_type":"4"}},{"id":2762282,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T20:10:55.000Z","date":"2021-03-16","kind":"tax_withholding","acquired":false,"shares":4356,"price":76.1,"value":331491.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the 2020 PRSUs."}],"balance_after":14904,"source":{"system":"sec-edgar","filing":"0001209191-21-024879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121024879/doc4.xml","form_type":"4"}},{"id":2762281,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T20:10:55.000Z","date":"2021-03-16","kind":"exercise","acquired":true,"shares":12600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 16, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units (\"2020 PRSUs\"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq \"Closing Price\" thresholds during the performance period from the grant date through Jan. 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein."}],"balance_after":19260,"source":{"system":"sec-edgar","filing":"0001209191-21-024879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121024879/doc4.xml","form_type":"4"}},{"id":2815599,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2021-03-03T21:33:05.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Employee Performance Restricted Stock Unit (\"PRSU\") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from March 1, 2021, through February 29, 2024 (the \"Performance Period\") and satisfaction of a continuing service requirement. The reporting person was granted a \"target\" number of PRSUs equal to 50% of the number reported in Column 5. This Form 4 reports the \"maximum\" number of PRSUs, which equals 200% of \"target\" PRSUs, in order to reflect the maximum number of common shares issuable to the reporting person pursuant to the PRSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $120, $130 or $145, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 25%, 50% or 100%, respectively, of the maximum amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs (less any shares previously vested). For the avoidance of doubt, shares may be issued following achievement of each price threshold, and Column 7 reports the maximum number of shares that may be issued pursuant to the PRSUs."}],"balance_after":15200,"derivative":{"expiration_date":"2024-02-29","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001209191-21-017584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017584/doc4.xml","form_type":"4"}},{"id":2815598,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-03T21:33:05.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":38850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2022, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":38850,"derivative":{"exercise_price":80.08,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":38850},"source":{"system":"sec-edgar","filing":"0001209191-21-017584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017584/doc4.xml","form_type":"4"}},{"id":2815597,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T21:33:05.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":6660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on May 15, 2022, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of August, November, February, and May. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":6660,"source":{"system":"sec-edgar","filing":"0001209191-21-017584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919121017584/doc4.xml","form_type":"4"}},{"id":3112044,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T08:00:20.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12000,"derivative":{"exercise_price":4.35,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-036179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919120036179/doc4.xml","form_type":"4"}},{"id":3206587,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2020-03-17T18:47:00.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Employee Performance Restricted Stock Unit (\"PRSU\") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the performance period from the grant date through January 3, 2022 (the \"Performance Period\") and satisfaction of a continuing service requirement."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."}],"balance_after":6300,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001209191-20-019765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120019765/doc4.xml","form_type":"4"}},{"id":3206586,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-17T18:47:00.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":132000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on March 16, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":132000,"derivative":{"exercise_price":36.33,"expiration_date":"2027-03-16","underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0001209191-20-019765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120019765/doc4.xml","form_type":"4"}},{"id":3253383,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-25T01:03:57.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":11392,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":11392},"source":{"system":"sec-edgar","filing":"0001179110-20-002175","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020002175/edgar.xml","form_type":"4"}},{"id":3253382,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-25T01:03:57.000Z","date":"2020-02-22","kind":"tax_withholding","acquired":false,"shares":4508,"price":21.83,"value":98409.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 4,508 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":116167,"source":{"system":"sec-edgar","filing":"0001179110-20-002175","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020002175/edgar.xml","form_type":"4"}},{"id":3253381,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-25T01:03:57.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":120675,"source":{"system":"sec-edgar","filing":"0001179110-20-002175","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020002175/edgar.xml","form_type":"4"}},{"id":3267187,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-18T21:15:12.000Z","date":"2020-02-14","kind":"exercise","acquired":false,"shares":7809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15616,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7809},"source":{"system":"sec-edgar","filing":"0001179110-20-001749","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001749/edgar.xml","form_type":"4"}},{"id":3267186,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-18T21:15:12.000Z","date":"2020-02-14","kind":"tax_withholding","acquired":false,"shares":2700,"price":21.1,"value":56970.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,700 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":109283,"source":{"system":"sec-edgar","filing":"0001179110-20-001749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001749/edgar.xml","form_type":"4"}},{"id":3267185,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-18T21:15:12.000Z","date":"2020-02-14","kind":"exercise","acquired":true,"shares":7809,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":111983,"source":{"system":"sec-edgar","filing":"0001179110-20-001749","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001749/edgar.xml","form_type":"4"}},{"id":3274496,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-13T23:38:22.000Z","date":"2020-02-12","kind":"exercise","acquired":false,"shares":11262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":33784},"source":{"system":"sec-edgar","filing":"0001179110-20-001581","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001581/edgar.xml","form_type":"4"}},{"id":3274495,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-13T23:38:22.000Z","date":"2020-02-12","kind":"tax_withholding","acquired":false,"shares":3894,"price":20,"value":77880.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,894 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":104174,"source":{"system":"sec-edgar","filing":"0001179110-20-001581","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001581/edgar.xml","form_type":"4"}},{"id":3274494,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-13T23:38:22.000Z","date":"2020-02-12","kind":"exercise","acquired":true,"shares":11262,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":108068,"source":{"system":"sec-edgar","filing":"0001179110-20-001581","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001581/edgar.xml","form_type":"4"}},{"id":3277490,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-12T22:59:26.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":32533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":32533,"derivative":{"exercise_price":0,"exercise_date":"2021-02-10","underlying":"Common Stock","underlying_shares":32533},"source":{"system":"sec-edgar","filing":"0001179110-20-001533","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001533/edgar.xml","form_type":"4"}},{"id":3277489,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2020-02-12T22:59:26.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":69174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":69174,"derivative":{"exercise_price":19.98,"exercise_date":"2021-02-10","expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":69174},"source":{"system":"sec-edgar","filing":"0001179110-20-001533","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020001533/edgar.xml","form_type":"4"}},{"id":3292258,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-04T21:21:09.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":23119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23119},"source":{"system":"sec-edgar","filing":"0001179110-20-000989","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020000989/edgar.xml","form_type":"4"}},{"id":3292257,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-04T21:21:09.000Z","date":"2020-02-03","kind":"tax_withholding","acquired":false,"shares":8275,"price":19.21,"value":158962.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 8,275 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":96806,"source":{"system":"sec-edgar","filing":"0001179110-20-000989","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020000989/edgar.xml","form_type":"4"}},{"id":3292256,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-04T21:21:09.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":23119,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":105081,"source":{"system":"sec-edgar","filing":"0001179110-20-000989","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911020000989/edgar.xml","form_type":"4"}},{"id":3488313,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-06-17T12:19:23.000Z","date":"2019-06-15","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001179110-19-007734","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019007734/edgar.xml","form_type":"4"}},{"id":3488312,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-17T12:19:23.000Z","date":"2019-06-15","kind":"tax_withholding","acquired":false,"shares":3408,"price":15.73,"value":53607.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,408 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":81962,"source":{"system":"sec-edgar","filing":"0001179110-19-007734","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019007734/edgar.xml","form_type":"4"}},{"id":3488311,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-17T12:19:23.000Z","date":"2019-06-15","kind":"exercise","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":85370,"source":{"system":"sec-edgar","filing":"0001179110-19-007734","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019007734/edgar.xml","form_type":"4"}},{"id":3499078,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T16:46:52.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director."}],"balance_after":12100,"derivative":{"exercise_price":3.69,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-19-035104","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1718108/000120919119035104/doc4.xml","form_type":"4"}},{"id":3639052,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-23T00:03:00.000Z","date":"2019-02-22","kind":"exercise","acquired":false,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":22784,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":11392},"source":{"system":"sec-edgar","filing":"0001179110-19-002463","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002463/edgar.xml","form_type":"4"}},{"id":3639051,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-23T00:03:00.000Z","date":"2019-02-22","kind":"tax_withholding","acquired":false,"shares":3939,"price":16.81,"value":66214.59,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,939 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":78495,"source":{"system":"sec-edgar","filing":"0001179110-19-002463","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002463/edgar.xml","form_type":"4"}},{"id":3639050,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-23T00:03:00.000Z","date":"2019-02-22","kind":"exercise","acquired":true,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":82434,"source":{"system":"sec-edgar","filing":"0001179110-19-002463","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002463/edgar.xml","form_type":"4"}},{"id":3653978,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-15T22:33:22.000Z","date":"2019-02-14","kind":"exercise","acquired":false,"shares":7809,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":23425,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7809},"source":{"system":"sec-edgar","filing":"0001179110-19-002005","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002005/edgar.xml","form_type":"4"}},{"id":3653977,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-15T22:33:22.000Z","date":"2019-02-14","kind":"tax_withholding","acquired":false,"shares":2700,"price":16.54,"value":44658.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,700 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":71042,"source":{"system":"sec-edgar","filing":"0001179110-19-002005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002005/edgar.xml","form_type":"4"}},{"id":3653976,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-15T22:33:22.000Z","date":"2019-02-14","kind":"exercise","acquired":true,"shares":7809,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":73742,"source":{"system":"sec-edgar","filing":"0001179110-19-002005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019002005/edgar.xml","form_type":"4"}},{"id":3657048,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-14T23:24:05.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":45046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":45046,"derivative":{"exercise_price":0,"exercise_date":"2020-02-12","underlying":"Common Stock","underlying_shares":45046},"source":{"system":"sec-edgar","filing":"0001179110-19-001932","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019001932/edgar.xml","form_type":"4"}},{"id":3657047,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2019-02-14T23:24:05.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":85922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":85922,"derivative":{"exercise_price":16.65,"exercise_date":"2020-02-12","expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":85922},"source":{"system":"sec-edgar","filing":"0001179110-19-001932","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019001932/edgar.xml","form_type":"4"}},{"id":3674977,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-05T21:10:11.000Z","date":"2019-02-03","kind":"exercise","acquired":false,"shares":23119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":23119,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23119},"source":{"system":"sec-edgar","filing":"0001179110-19-001316","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019001316/edgar.xml","form_type":"4"}},{"id":3674976,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-05T21:10:11.000Z","date":"2019-02-03","kind":"tax_withholding","acquired":false,"shares":8317,"price":16.12,"value":134070.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 8,317 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":65933,"source":{"system":"sec-edgar","filing":"0001179110-19-001316","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019001316/edgar.xml","form_type":"4"}},{"id":3674975,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-05T21:10:11.000Z","date":"2019-02-03","kind":"exercise","acquired":true,"shares":23119,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":74250,"source":{"system":"sec-edgar","filing":"0001179110-19-001316","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911019001316/edgar.xml","form_type":"4"}},{"id":3890947,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-06-18T20:23:52.000Z","date":"2018-06-15","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":6875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001179110-18-008700","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018008700/edgar.xml","form_type":"4"}},{"id":3890946,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-18T20:23:52.000Z","date":"2018-06-15","kind":"tax_withholding","acquired":false,"shares":3254,"price":19.02,"value":61891.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,254 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":51131,"source":{"system":"sec-edgar","filing":"0001179110-18-008700","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018008700/edgar.xml","form_type":"4"}},{"id":3890945,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-18T20:23:52.000Z","date":"2018-06-15","kind":"exercise","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54385,"source":{"system":"sec-edgar","filing":"0001179110-18-008700","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018008700/edgar.xml","form_type":"4"}},{"id":4037253,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-23T22:13:35.000Z","date":"2018-02-22","kind":"exercise","acquired":false,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":34176,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":11392},"source":{"system":"sec-edgar","filing":"0001179110-18-002766","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018002766/edgar.xml","form_type":"4"}},{"id":4037252,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-23T22:13:35.000Z","date":"2018-02-22","kind":"tax_withholding","acquired":false,"shares":3939,"price":19.28,"value":75943.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 3,939 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":47510,"source":{"system":"sec-edgar","filing":"0001179110-18-002766","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018002766/edgar.xml","form_type":"4"}},{"id":4037251,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-23T22:13:35.000Z","date":"2018-02-22","kind":"exercise","acquired":true,"shares":11392,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51449,"source":{"system":"sec-edgar","filing":"0001179110-18-002766","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018002766/edgar.xml","form_type":"4"}},{"id":4052290,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-16T21:07:47.000Z","date":"2018-02-14","kind":"grant","acquired":true,"shares":31234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":31234,"derivative":{"exercise_price":0,"exercise_date":"2019-02-14","underlying":"Common Stock","underlying_shares":31234},"source":{"system":"sec-edgar","filing":"0001179110-18-002257","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018002257/edgar.xml","form_type":"4"}},{"id":4052289,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2018-02-16T21:07:47.000Z","date":"2018-02-14","kind":"grant","acquired":true,"shares":54780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":54780,"derivative":{"exercise_price":18.41,"exercise_date":"2019-02-14","expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":54780},"source":{"system":"sec-edgar","filing":"0001179110-18-002257","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018002257/edgar.xml","form_type":"4"}},{"id":4076624,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-05T21:25:01.000Z","date":"2018-02-03","kind":"exercise","acquired":false,"shares":23120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":46238,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23120},"source":{"system":"sec-edgar","filing":"0001179110-18-001493","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018001493/edgar.xml","form_type":"4"}},{"id":4076623,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-05T21:25:01.000Z","date":"2018-02-03","kind":"tax_withholding","acquired":false,"shares":8265,"price":18.37,"value":151828.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 8,265 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":40057,"source":{"system":"sec-edgar","filing":"0001179110-18-001493","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018001493/edgar.xml","form_type":"4"}},{"id":4076622,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-05T21:25:01.000Z","date":"2018-02-03","kind":"exercise","acquired":true,"shares":23120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48322,"source":{"system":"sec-edgar","filing":"0001179110-18-001493","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911018001493/edgar.xml","form_type":"4"}},{"id":4279354,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-06-16T20:10:48.000Z","date":"2017-06-15","kind":"exercise","acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":13750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001179110-17-009188","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017009188/edgar.xml","form_type":"4"}},{"id":4279353,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-16T20:10:48.000Z","date":"2017-06-15","kind":"tax_withholding","acquired":false,"shares":2583,"price":13.05,"value":33708.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,583 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":25202,"source":{"system":"sec-edgar","filing":"0001179110-17-009188","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017009188/edgar.xml","form_type":"4"}},{"id":4279352,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-16T20:10:48.000Z","date":"2017-06-15","kind":"exercise","acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27785,"source":{"system":"sec-edgar","filing":"0001179110-17-009188","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017009188/edgar.xml","form_type":"4"}},{"id":4424935,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-24T21:05:08.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":45568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":45568,"derivative":{"exercise_price":0,"exercise_date":"2018-02-22","underlying":"Common Stock","underlying_shares":45568},"source":{"system":"sec-edgar","filing":"0001179110-17-003117","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003117/edgar.xml","form_type":"4"}},{"id":4424934,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-02-24T21:05:08.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":72925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":72925,"derivative":{"exercise_price":12.07,"exercise_date":"2018-02-22","expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":72925},"source":{"system":"sec-edgar","filing":"0001179110-17-003117","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003117/edgar.xml","form_type":"4"}},{"id":4466541,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-07T00:01:07.000Z","date":"2017-02-03","kind":"exercise","acquired":false,"shares":23120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":69358,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":23120},"source":{"system":"sec-edgar","filing":"0001179110-17-001808","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001808/edgar.xml","form_type":"4"}},{"id":4466540,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-07T00:01:07.000Z","date":"2017-02-03","kind":"tax_withholding","acquired":false,"shares":9085,"price":12.26,"value":111382.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 9,085 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":20910,"source":{"system":"sec-edgar","filing":"0001179110-17-001808","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001808/edgar.xml","form_type":"4"}},{"id":4466539,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-07T00:01:07.000Z","date":"2017-02-03","kind":"exercise","acquired":true,"shares":23120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29995,"source":{"system":"sec-edgar","filing":"0001179110-17-001808","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001808/edgar.xml","form_type":"4"}}]}